Internal Reference Number: FOI_8078
Date Request Received: 05/08/2024 00:00:00
Date Request Replied To: 21/08/2024 00:00:00
This response was sent via: By Email
Request Summary: Atopic Dermatitis
Request Category: Companies
| Question Number 1: How many patients were treated in the last 4 months (April to July 2024) by the dermatology department with each of the following products: • Abrocitinib • Acitretin • Alitretinoin • Azathioprine • Baricitinib • Ciclosporin • Dupilumab • Lebrikizumab • Methotrexate • Mycophenolate mofetil • Pimecrolimus • Phototherapy (UVB or PUVA) - for Atopic Dermatitis only • Tacrolimus ointment • Tralokinumab • Upadacitinib | |
| Answer To Question 1: • Abrocitinib <5 • Acitretin 27 • Alitretinoin 5 • Azathioprine <5 • Baricitinib 0 • Ciclosporin 9 • Dupilumab 25 • Lebrikizumab 0 • Methotrexate 32 • Mycophenolate mofetil <5 • Pimecrolimus 10 • Phototherapy (UVB or PUVA) - for Atopic Dermatitis only 11 • Tacrolimus ointment 34 • Tralokinumab <5 • Upadacitinib <5 | |
| Question Number 2: Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group: • Age 6-11 • Age 12-17 • Age 18 and above | |
| Answer To Question 2: • Age 6-11 5 • Age 12-17 8 • Age 18 and above 144 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
